Multiple Myeloma, An Issue of Hematology/Oncology Clinics

Kenneth C. Anderson

Description

This issue of Hematology/Oncology Clinics of North America, devoted to Multiple Myeloma, is edited by Dr. Kenneth C. Anderson. Articles in this issue include: Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma; Diagnosis and Risk Stratification in Myeloma; Treatment of Newly Diagnosed Transplant Eligible Patients; Treatment of Newly Diagnosed Transplant Ineligible Patients; Treatment of Relapsed/Refractory Myeloma; Maintenance Therapy; Novel Targeted Therapies; Novel Immune-based Therapies; Allotransplantation in Myeloma; and Waldenstrom’s Macroglobulinemia.

Sujets

• Hermatology
• Medical
• Médecine

Informations

• Publié par: Elsevier
• Date de parution: 22 novembre 2014
• Nombre de lectures: 0
• EAN13: 9780323326148
• Langue: English
• Poids de l'ouvrage: 2 Mo

Extrait

Clinics Review Articles Hematology/Oncology Clinics of North America
Multiple Myeloma

Dr, Kenneth C. Anderson, MD
Department of Hematology/Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
ISSN  0889-8588 Volume 28 • Number 5 • October 2014
Table of Contents
Cover image
Title page
Contributors
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA
Forthcoming Issues
Recent Issues
Preface: Multiple Myeloma
Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Key points
Introduction
Recognition of monoclonal gammopathies
Monoclonal gammopathy of undetermined significance
Management of MGUS
Smoldering (asymptomatic) multiple myeloma
Summary
Diagnosis and Risk Stratification in Multiple Myeloma
Key points
Clinical presentation
Differential diagnosis
Diagnostic workup of MM
Prognostic factors
Disease characteristics
Patient characteristics
Models combining patient and disease characteristics
ISS, FISH, and failure to achieve CR after induction therapy
Concluding remarks and future perspectives
Treatment of Transplant-Eligible Patients with Multiple Myeloma in 2014
Key points
Introduction
Defining an optimal induction regimen
Role of HDT and SCT
Preventing relapse
Summary and future directions
Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation
Key points
Introduction
Thalidomide-based regimens
Bortezomib-based regimens
Lenalidomide-based regimens
Unfit patients
Maintenance therapy
Future directions
Maintenance Therapy for Multiple Myeloma
Key points
Introduction
Maintenance approaches for patients ineligible for transplantation
Maintenance approaches for patients eligible for transplantation
Summary
Relapsed and Refractory Multiple Myeloma
Key points
Introduction
The achievement of complete remission
Prognostic factors
Current treatment options for RRMM
The future of therapy: emerging agents and novel treatment strategies
Summary
Allogeneic Stem Cell Transplantation for Multiple Myeloma
Key points
Introduction
History
Reduced-intensity conditioning regimens
GVHD and relapse
HI-risk myeloma
Prospective comparisons of tandem ASCT versus ASCT-AlloSCT
Recent reports
Summary and future studies
Novel Targeted Agents in the Treatment of Multiple Myeloma
Key points
Introduction
Second-generation proteosome inhibitors
Cell signaling agents
Targeting the bone marrow microenvironment
Cell cycle inhibitors
Monoclonal antibodies
Novel cytotoxics
Summary
Immunotherapy Strategies in Multiple Myeloma
Key points
Passive-specific immunotherapy
Active-specific immunotherapy
Future directions
Waldenström Macroglobulinemia
Key points
Introduction
Epidemiology
Biology
Clinical features
Morbidity mediated by the effects of IgM
Laboratory investigations and findings
Prognosis and risk stratification
Treatment of Waldenström macroglobulinemia
Maintenance therapy
High-dose therapy and stem cell transplantation
Response criteria in Waldenström macroglobulinemia
Summary
Index
Contributors
CONSULTING EDITORS
GEORGE P. CANELLOS, MD
William Rosenberg Professor of Medicine; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
H. FRANKLIN BUNN, MD
Professor of Medicine; Division of Hematology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
EDITOR
KENNETH C. ANDERSON, MD
Department of Hematology/Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
AUTHORS
KENNETH C. ANDERSON, MD
Department of Hematology/Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
JOOEUN BAE, PhD
Instructor, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
WILLIAM BENSINGER, MD
Member, Fred Hutchinson Cancer Research Center; Professor, Division of Oncology, University of Washington, Seattle, Washington
JORGE J. CASTILLO, MD
Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
DHARMINDER CHAUHAN, PhD
Department of Hematology/Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
THIERRY FACON, MD
Hematology Department, University Hospital, Lille, France
SILVIA GENTILI, MD
Department of Hematology, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy
SERGIO GIRALT, MD
Attending Physician, Adult BMT Service, Memorial Sloan Kettering Cancer Center; Professor of Medicine, Weill Cornell Medical College, New York, New York
TERU HIDESHIMA, MD, PhD
Department of Hematology/Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
CYRILLE HULIN, MD
Hematology Department, University Hospital, Nancy, France
ZACHARY R. HUNTER, PhD
Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
ROBERT A. KYLE, MD
Professor of Medicine and Laboratory Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota
HEATHER LANDAU, MD
Assistant Attending Physician, Adult BMT Service, Memorial Sloan Kettering Cancer Center; Associate Professor of Medicine, Weill Cornell Medical College, New York, New York
JACOB LAUBACH, MD
Department of Hematology/Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
SAGAR LONIAL, MD
Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia
MARIA-VICTORIA MATEOS, MD, PhD
Consultant Physician, Hematology Department, University Hospital of Salamanca, Salamanca, Spain
PHILIP L. MCCARTHY, MD
Professor of Oncology and Internal Medicine, Department of Medicine, Blood and Marrow Transplant Program, Roswell Park Cancer Institute, State University of New York at Buffalo, Buffalo, New York
GIAMPAOLO MERLINI, MD
Department of Molecular Medicine, Amyloidosis Research and Treatment Center, University Hospital Policlinico San Matteo, Pavia, Italy
PHILIPPE MOREAU, MD
Hematology Department, UMR892, University Hospital, Nantes, France
NIKHIL C. MUNSHI, MD
Professor, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
ANTONIO PALUMBO, MD
Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy
S. VINCENT RAJKUMAR, MD
Professor of Medicine and Chair, Myeloma Amyloidosis Dysproteinemia Group, Division of Hematology, Mayo Clinic, Rochester, Minnesota
PAUL G. RICHARDSON, MD
Department of Hematology/Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
JESUS F. SAN-MIGUEL, MD, PhD
Professor and Director, Clinical and Translational Medicine, Hematology Department, Clinica Universidad de Navarra, Pamplona, Navarra, Spain
PIETER SONNEVELD, MD, PhD
Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
STEVEN P. TREON, MD, MA, PhD
Bing Center for Waldenström’s Macroglobulinemia, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
NIELS W.C.J. VAN DE DONK, MD, PhD
Department of Hematology, University Medical Center Utrecht, Utrecht, The Netherlands
CINDY VARGA, MD
Department of Hematology/Oncology, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA

Forthcoming Issues
December 2014
Bone Marrow Transplantation
Bipin N. Savani and
Mohamad Mohty, Editors

February 2015
Colorectal Cancer
Leonard B. Saltz, Editor

April 2015
Bladder Cancer
Joaquin Bellmunt, Editor

Recent Issues
August 2014
Iron Disorders
Matthew M. Heeney and
Alan R. Cohen, Editors

June 2014
Melanoma
F. Stephen Hodi, Editor

April 2014
Emerging Therapies Targeting the
Pathophysiology of Sickle Cell Disease
Elliot P. Vichinsky, Editor

ISSUE OF RELATED INTEREST
Clinics in Laboratory Medicine, September 2014 (Vol. 34, Issue 3)
Anticoagulants
Jerrold H. Levy, Editor
Available at: http://www.labmed.theclinics.com/
Preface
Multiple Myeloma
Kenneth C. Anderson, MD [e-mail] , Department of Hematology/Oncology, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA
Kenneth C. Ande